Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltartoxatug Injection for Prevention of Post-Traumatic Tetanus
ChiCTR2600117128Phase 4Not yet recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of siltartoxatug in Tetanus, sponsored by Fujian Provincial Hospital. Primary endpoint: Tetanus antitoxin neutralizing antibody titer. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
siltartoxatug
03
Conditions
Tetanus
Beyond the preview
Go deeper on ChiCTR2600117128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117128.